On July 7, 2023, Michael L. Jones, Executive Director, Finance and Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. informed the Company of his intention to resign from the Company. Mr. Jones will continue with the Company as Executive Director, Finance through April 2024 to assist with the transition of his roles and responsibilities. His resignation is not due to any disagreement on any matter relating to the Company’s operations, policies, or practices.

On July 10, 2023, the Board of Directors of the Company appointed Anthony Doyle, the Company’s Chief Financial Officer, to serve as interim Principal Accounting Officer, effective as of the same date. The biographical information required by Items 401(b), (d), and (e) of Regulation S-K for Mr. Doyle was previously reported in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on April 27, 2023. Mr. Doyle does not have a family relationship with any of the Company’s officers or directors and has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There will be no change to Mr. Doyle’s compensation arrangements with the Company as a result of this appointment.